Predictors included in the final models were age, mode of detection, sublocalisation, presence of ductal carcinoma in situ (DCIS), differentiation grade, hormonal receptor status ± endocrine treatment, HER2 status, axillary lymph node dissection and pCR. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.